<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260125068662N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-02-16</date_registration>
      <primary_sponsor>Khomein University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Aromatherapy on Pain and Hemodynamic Indices</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the effect of aromatherapy with rosemary and Mentha piperita essential oils on pain and hemodynamic indicators in patients after laparoscopic cholecystectomy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-02-09</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>93</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/88800</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Block randomization will be employed to ensure the concealment of treatment allocation. For this purpose, the SealedEnvelope website will be utilized. The total sample size, the number of study arms (groups), and the desired block sizes (blocks of 6) will be entered into the aforementioned website. The output will be a randomized list detailing the number of subjects allocated to each study group (Control and Intervention).

Subsequently, each eligible research subject will be assigned a sequential code based on their order of presentation/enrollment. By matching this code with the generated block randomization list, participating patients will be allocated to either the Intervention Group or the Control Group, Blinding description: The essential oils (active agents) and the placebo will be placed in identical, opaque, and uniformly labeled bottles. Each bottle will be coded, with only the patient’s unique identification code inscribed upon it.

All acquired data will be recorded and entered into the statistical software using only the patient identification codes.

The statistical analyst responsible for data processing and analysis will not have access to the group codes (i.e., will remain blinded). The group allocation will only be revealed after the analysis is complete.</study_design>
      <phase>3</phase>
      <hc_freetext>cholecystectomy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: 3 drops of 100% Peppermint essential oil (for the mint group), prepared from the Giyah Kala company, are dropped onto a sterile cotton ball. This is attached to the patient’s collar at a distance of 20 cm, and the patient is instructed to perform deep inhalations for 5 to 10 minutes. Intervention 2: Intervention group2 : 3 drops of 25% Rosmary essential oil (for the mint group), prepared from the Giyah Kala company, are dropped onto a sterile cotton ball. This is attached to the patient’s collar at a distance of 20 cm, and the patient is instructed to perform deep inhalations for 5 to 10 minutes. Intervention 3: Control group: In the control group, the intervention is matched to the test group in terms of time and method of execution. The difference is that instead of the essential oil, 3 drops of scented distilled water will be used.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is No further information is available</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Salehi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Khomein University of Medical Sciences, Qods Blvd , Khomein</address>
        <city>Khomein</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3819749058</zip>
        <telephone>+98 86 3280 0813</telephone>
        <email>fatemeh.salehi1551@gmail.com</email>
        <affiliation>Khomein University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh Salehi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Khomein University of Medical Sciences, Blvd Qods , Khomein</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3819749058</zip>
        <telephone>+98 86 3280 0813</telephone>
        <email>fatemeh.salehi1551@gmail.com</email>
        <affiliation>Khomein University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients eligible for elective cholecystectomy surgery are adults (above 18 years of age)
who have at least basic literacy (able to read and write)
They must have no impairment of smell, speech, hearing, or vision
no known allergy to peppermint or rosemary based on the initial patient interview and medical records
Patients should have no history of pulmonary or respiratory diseases
no substance abuse
no use of anticoagulant medications
no history of hypertension, and no psychiatric disorders. In addition, they should have no history of epilepsy or chronic headaches
not be pregnant
The postoperative pain intensity should be three or greater on the Visual Analogue Scale (Visual Analog Scale)
Before starting the intervention, the effects of anesthesia must have completely worn off, and the patient should be fully conscious after the operation
not connected to a ventilator, not receiving oxygen therapy, and able to breathe spontaneously</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Use of analgesic or narcotic medications for pain relief beyond the routine postoperative orders.
Presence of physical complications or instability in hemodynamic and physiological status, such as occurrence of cardiac arrhythmia, respiratory problems, abnormal bleeding
blood pressure instability (including unusual increase or decrease during surgery or immediately after surgery in the recovery room), as well as any other abnormal condition reported by operating room staff or documented in the patient’s file.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z90.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acquired absence of other parts of digestive tract</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: 3 drops of 100% Peppermint essential oil (for the mint group), prepared from the Giyah Kala company, are dropped onto a sterile cotton ball. This is attached to the patient’s collar at a distance of 20 cm, and the patient is instructed to perform deep inhalations for 5 to 10 minutes.</i_keyword>
      <i_keyword>Intervention group2 : 3 drops of 25% Rosmary essential oil (for the mint group), prepared from the Giyah Kala company, are dropped onto a sterile cotton ball. This is attached to the patient’s collar at a distance of 20 cm, and the patient is instructed to perform deep inhalations for 5 to 10 minutes.</i_keyword>
      <i_keyword>Control group: In the control group, the intervention is matched to the test group in terms of time and method of execution. The difference is that instead of the essential oil, 3 drops of scented distilled water will be used</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Postoperative pain intensity based on Visual Analog Scale. Timepoint: before the intervention (aromatherapy) and at 5, 15, 30, and 60 minutes after aromatherapy. Method of measurement: visual Analog Scale (VAS) will be used to determine the presence and severity of pain.</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: Heart rate monitoring will be performed before the intervention (aromatherapy) and at 5, 15, 30, and 60 minutes after aromatherapy. Method of measurement: A portable monitor is used to measure heart rate.</prim_outcome>
      <prim_outcome>Systolic blood pressure. Timepoint: Blood pressure control will be performed before the intervention (aromatherapy) and at 5, 15, 30, and 60 minutes after aromatherapy. Method of measurement: Using a blood pressure monitor, portable monitor.</prim_outcome>
      <prim_outcome>Respiratory rate. Timepoint: Breathing rate will be monitored before the intervention (aromatherapy) and at 5, 15, 30, and 60 minutes after aromatherapy. Method of measurement: The number of breaths was also counted for one minute by the researcher using a stopwatch.</prim_outcome>
      <prim_outcome>Diastolic blood pressure. Timepoint: Blood pressure control will be performed before the intervention (aromatherapy) and at 5, 15, 30, and 60 minutes after aromatherapy. Method of measurement: Using a blood pressure monitor, portable monitor.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Khomein University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-01-12</approval_date>
        <contact_name>Ethics committee of Khomein University of Medical Sciences</contact_name>
        <contact_address>Khomein University of Medical Sciences, Qods Blvd , Khomein Khomein Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
